Trinity Biotech Plc Sponsored ADR Class A Aktie News

DUBLIN, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with a leading bioinformatics company to conduct advanced analysis on clinical trial data for EpiCapture, the company's PCR-based epigenetic ...

DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that the Company welcomes the indicated intention of its largest investor and primary lender, Perceptive Advisors, to submit a proposal that, if implemented, would fac...

DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the $1.00 per s...

DUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director.

Approval Facilitates Immediate Offshored and Outsourced Manufacturing Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity's Broader Profitability and Growth Objectives DUBLIN, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB...

New York State Department of Health (NYSDOH) clinical laboratory permit facilitates Q3 2025 launch of the FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test for hypertensive disorders of pregnancy New York State Department of Health (NYSDOH) clinical laboratory permit facilitates Q3 2025 launch of the FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test for hypertensive disorders of p...

Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company's next-generation CGM+ biosensor platform Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company's next-generation CGM+ biosensor platform

FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, incl...